EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSOKIG00005009425
Gene Symbol: EGLN3
3 Cross references
147 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSOKIG00005014584
Gene Symbol: EGLN3
1 Cross references
194 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSOKIG00005046926
Gene Symbol: EPAS1
3 Cross references
205 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSOKIG00005018762
Gene Symbol: EPAS1
3 Cross references
205 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSOKIG00005027418
Gene Symbol: ECE1
1 Cross references
224 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSOKIG00005013865
Gene Symbol: EDNRA
3 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOKIG00005026991
Gene Symbol: LOC109901296
3 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOKIG00005050709
Gene Symbol: EDNRB
3 Cross references
192 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOKIG00005008707
Gene Symbol: EDNRB
1 Cross references
192 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOKIG00005041124
Gene Symbol: LOC109875413
3 Cross references
190 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSOKIG00005003546
Gene Symbol: LOC109881007
3 Cross references
201 Possible Orthologues:

Endothelin-Converting Enzyme 1

Ensembl ID : ENSOKIG00005040402
Gene Symbol: LOC109891043
3 Cross references
224 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).